These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238 [TBL] [Abstract][Full Text] [Related]
4. Targeted therapies for cutaneous melanoma. Kee D; McArthur G Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943 [TBL] [Abstract][Full Text] [Related]
5. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Capovilla M Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719 [TBL] [Abstract][Full Text] [Related]
6. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067 [TBL] [Abstract][Full Text] [Related]
7. Is it good or bad to find a BRAF mutation? Flaherty KT J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552 [No Abstract] [Full Text] [Related]
8. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive. Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321 [TBL] [Abstract][Full Text] [Related]
10. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. Mochel MC; Hammond MR; Frederick DT; Alora-Palli MB; Piris A; Flaherty KT; Hoang MP J Am Acad Dermatol; 2015 Sep; 73(3):491-9.e2. PubMed ID: 26190239 [TBL] [Abstract][Full Text] [Related]
11. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367 [TBL] [Abstract][Full Text] [Related]
12. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; MandalĂ M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
13. Targeted therapy resistance mechanisms and therapeutic implications in melanoma. Chen G; Davies MA Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945 [TBL] [Abstract][Full Text] [Related]
14. A new standard of care for metastatic melanoma? Sharma SP Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559 [No Abstract] [Full Text] [Related]
15. Emerging targeted therapies for melanoma. Johnson DB; Pollack MH; Sosman JA Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822 [TBL] [Abstract][Full Text] [Related]
17. Oncogenetics of melanoma: basis for molecular diagnostics and therapy. Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632 [TBL] [Abstract][Full Text] [Related]
18. Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493 [TBL] [Abstract][Full Text] [Related]
19. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
20. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Jang S; Atkins MB Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]